We believe these data underscore the potential of CagriSema to address unmet medical needs in obesity and support long-term disease management." The NDA is based on results from REDEFINE 1, a 68-week, phase 3, randomized, double-blind, placebo-and active-controlled trial that evaluated the efficacy and safety of once-weekly CagriSema compared to semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone, or placebo, all as an adjunct to lifestyle intervention in 3,417 adults with obesity (BMI 30 kg/m 2 ) or overweight (BMI 27 kg/m 2 ) with one or more obesity-related complications and without diabetes, and REDEFINE 2, a double-blind, randomized, placebo-controlled, 68-week, phase 3 trial that evaluated the efficacy and safety of once-weekly CagriSema versus placebo, as an adjunct to lifestyle intervention in 1,206 adults with type 2 diabetes and either obesity (BMI 30 kg/m 2 ) or overweight (BMI 27 kg/m 2 )
Clinically, participants demonstrated a significant reduction in CARS scores (median decrease: 4.5 points
While certain methods employing laborious pre-column chemical derivatization combined with fluorescence or MS/MS detection can reach lower limits in the fmol/L or pmol/L range [57, 69], they usually compromise on the scope of analyzed compounds and analysis throughput
For quicker results, use a de tan face pack 23 times during the week
Iron overload in alcoholic liver disease: Underlying mechanisms, detrimental effects, and potential therapeutic targets
The key binding residues for GSH_a are E184, D180, S361, and Q359 (Table 3)
